血清抗NMDA受体抗体与卒中后长期临床结局:PROSCIS-B研究
该研究基于PROSCIS-B前瞻性队列,纳入583例首次卒中患者,检测7天内血清NMDAR1-abs。结果显示NMDAR1-abs血清阳性率为13%,总体与1年功能结局无关,但高滴度(≥1:320)与不良功能结局相关;血清阳性与3年内复发性血管事件或死亡风险增加独立相关。
要点
- NMDAR1-abs血清阳性率13%,总体与1年功能结局无关。
- 高滴度(≥1:320)患者1年功能结局更差(OR=3.47)。
- 血清阳性者3年内复发性血管事件或死亡风险增加(HR=1.83)。
核心结论
- NMDAR1-abs血清阳性总体与卒中后1年功能结局无关,但高滴度(≥1:320)与不良功能结局相关。
- NMDAR1-abs血清阳性与首次卒中后3年内复发性血管事件或死亡风险增加独立相关。
研究设计与样本
- 研究使用PROSCIS-B前瞻性队列数据,纳入583例首次卒中患者,39%为女性,中位NIHSS为2(IQR 1-4)。
- 在卒中后7天内检测血清NMDAR1-abs(IgM、IgA、IgG),并随访1年功能结局(mRS)及3年内复合终点事件。
主要发现
- 76例(13%)患者NMDAR1-abs血清阳性。
- NMDAR1-abs血清阳性与1年功能结局无关(OR=1.27;95%CI 0.77-2.09)。
- 高滴度组(1:320;1:1000)患者功能结局更差(OR=3.47;95%CI 1.54-7.80)。
- 血清阳性患者发生二次血管事件或死亡的风险增加(HR=1.83;95%CI 1.10-3.05)。
临床怎么用
- 对首次卒中患者,可考虑检测血清NMDAR1-abs以识别高滴度(≥1:320)人群,其1年功能结局可能更差。
- NMDAR1-abs血清阳性提示3年内复发性血管事件或死亡风险增加,或可加强二级预防和随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background and Purpose- NMDAR1-abs (anti-N-Methyl-D-Aspartate receptor GluN1 antibodies), predominantly known in the context of autoimmune encephalitis, have been observed in serum of healthy individuals. A previous study found smaller stroke magnetic resonance imaging lesion growth in seropositive patients, suggesting a neuroprotective effect of these antibodies. The impact of NMDAR1-abs seropositivity on long-term functional outcome and recurrent vascular events and death after first-ever stroke remains unclear. Methods- Data from the Prospective Cohort with Incident Stroke-Berlin were used. NMDAR1-abs (ie, IgM, IgA, and IgG) were measured in serum within 7 days after first stroke. Outcomes of interest included modified Rankin Scale at one year and the time-to-event of a combined end point (recurrent stroke, myocardial infarction, and all-cause mortality) within 3 years. We calculated odds ratios from adjusted partial proportional odds models and subsequently compared outcome of patients with low titers (1:10; 1:32; and 1:100), and high titers (1:320; 1:1000) to seronegative patients. Furthermore, we estimated hazard ratios for a secondary vascular event or death in NMDAR1-abs seropositive compared to seronegative patients in models adjusted for confounders. Results- The analyses included 583 patients with antibody measurements (39% female, median National Institutes of Health Stroke Scale:2, IQR:1-4), and NMDAR1-abs were observed in 76 (13%) patients. NMDAR1-abs seroprevalence was not associated with functional outcome (odds ratio=1.27; 95% CI, 0.77-2.09); sub-group analyses, however, showed worse outcome in patients with high titers (odds ratio=3.47; 95% CI, 1.54-7.80). Seropositive patients had an increased risk for a secondary vascular event or death (hazard ratios =1.83, 95% CI, 1.10-3.05). Conclusions- In our study, NMDAR1-abs seropositivity was not associated with functional outcome at one year after stroke, however, high titers (≥1:320) were associated with poor functional outcome. Furthermore, NMDAR1-abs seropositivity was associated with increased cardiovascular risk within 3 years after first stroke, independently from other risk factors. Clinical Trial Registration- URL: https://www.clinicaltrials.gov. Unique identifier: NCT01363856.
引用
- Sperber PS, Siegerink B, Huo S, et al. Serum Anti-NMDA (N-Methyl-D-Aspartate)-Receptor Antibodies and Long-Term Clinical Outcome After Stroke (PROSCIS-B). Stroke. 2019. PMID: 31526121. doi:10.1161/STROKEAHA.119.026100
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。